Review for progress and current status of human papillomavirus prophylactic vaccine
10.3969/j.issn.1005-1678.2016.06.08
- VernacularTitle:人乳头瘤病毒预防性疫苗的研究进展和应用现状
- Author:
Yunbing LI
;
Shuo SONG
;
Daning WANG
;
Zhihai LI
;
Ningshao XIA
;
Shaowei LI
- Publication Type:Journal Article
- Keywords:
human papillomavirus;
major capsid protein L1;
cervical cancer;
vaccines
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(6):33-37
- CountryChina
- Language:Chinese
-
Abstract:
Persistant infection of high-risk human papillomavirus (HPV) is the primary cause leading to cervical cancer, which is ranked as second cancer threatening the health of women following breast cancer.Development of HPV vaccine is very important because there is no effective therapeutics for cervical cancer.Three currently licensed HPV vaccines based on major capsid protein L1 in the foreign market confered good safety and efficacy in clinical trials, but the current price is expensive due to high cost, which limits the wide application in developing countries.So far, the vaccines have not been launced in China market.Here, we review the progress and the current status of the HPV vaccine, which will attract the readers’ interest on the forthcoming emergence of HPV vaccine in China.
